HALO

News Halozyme (HALO) Q2 EPS Jumps 69%

14d ago

News Halozyme (HALO) Raises 2024 Financial Guidance, Stock Up 13%

14d ago

News This Exxon Mobil Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

14d ago

News Halozyme's (HALO) ENHANZE Product Gets New Patent Grant in EU

14d ago

Insider trade Sale by Helen Torley (PRESIDENT AND CEO)

19d ago

Insider trade Sale by Helen Torley (PRESIDENT AND CEO)

19d ago

Insider trade Sale by Helen Torley (PRESIDENT AND CEO)

19d ago

News Halozyme outlines ENHANZE royalties exceeding $1B in 2026 while launching a new $1B buyback

21d ago

News Halozyme Therapeutics Non-GAAP EPS of $1.60 beats by $0.08, revenue of $376.71M beats by $17.66M

21d ago

News Argenx wins FDA nod to broaden Vyvgart label in myasthenia gravis

23d ago

Insider trade Sale by Bernadette Connaughton

27d ago

Insider trade Sale by Helen Torley (PRESIDENT AND CEO)

55d ago

News Vertex Pharma in pact with Halozyme for Hypercon drug delivery tech

56d ago

News Halozyme appoints David Ramsay as interim CFO

82d ago

News J&J wins FDA nod for multiple myeloma therapy

88d ago

Insider trade Sale by Helen Torley (PRESIDENT AND CEO)

89d ago

News Halozyme declines after Q4 bottom line miss, reiterates 2026 guidance

103d ago

Insider trade Sale by Helen Torley (PRESIDENT AND CEO)

104d ago

News Halozyme outlines $1.71B–$1.81B 2026 revenue target as new subcutaneous technologies expand pipeline

104d ago

SEC filing HALO Reports $1.397B Revenue, $868M Royalty, +38% YoY, Guides 2026 Rev $1.710-1.810B, +22-30% YoY, Adj EBITDA $1.125-1.205B, +71-83% YoY, EPS $7.75-8.25, +87-99% YoY

104d ago

News Halozyme Therapeutics Q4 2025 Earnings Preview

105d ago

Short volume Short volume 79% of volume (7.4σ)

123d ago

News Halozyme Therapeutics Projects Sustained Growth Well Into 2040

124d ago

News Halozyme raises outlook, buys Surf Bio

125d ago

SEC filing HALO Raises 2025 Revenue to $1.39B, 36% YoY Growth, 2026 Guidance to $1.71-1.81B, Acquires Surf Bio for up to $400M

125d ago